CLEARWATER, Fla., April 27, 2006 (PRIMEZONE) -- Maui General Stores Inc. dba Trinity BioGenics Corp. (OTCBB:MAUG), a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with immune therapy, is pleased to announce that the BlackBerry-AGORACOM Small Cap Centre featured Trinity BioGenics, showcasing the Company's revolutionary Biological Medicine and Human Stem Cell technology.
Trinity BioGenics Featured to Over 4.3 Million BlackBerry Users Worldwide
The Trinity BioGenics feature story is accessible by all 4.3 million BlackBerry devices from Monday, April 24 until Monday, May 1. The BlackBerry-AGORACOM Small Cap Center has the ability to reach 4.3 million BlackBerry devices around the world. The BlackBerry-AGORACOM Small Cap Center joins a small but elite group of Tier-1 financial content providers to service the highly coveted audience of BlackBerry users that only includes The Financial Times, Business Week, Forbes, Marketwatch and The Street.com. Currently, BlackBerry is available in 50 countries but the company will have extended its reach to 90 countries by the end of 2006.
Trinity BioGenics CEO, Lawrence Stowe, stated, "Being featured on all BlackBerry devices is an unbelievable accomplishment and a testament to the hard work and dedication of the entire team." Dr. Stowe continued to say, "BlackBerry's worldwide acceptance and reach is unparalleled, and to headline as the exclusive feature story is a tremendous accomplishment for our company."
For all future Trinity BioGenics investor relations needs, investors are asked to visit the Trinity BioGenics IR Hub at http://www.agoracom.com/IR/TrinityBioGenics where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors can e-mail questions and correspondence to MAUG@agoracom.com where they can also request addition to the investor e-mail list for future press releases and updates in real time.
About Trinity BioGenics Corp.
Trinity BioGenics Corp. works exclusively within the Adult Stem Cell and Biological Medicine areas. The Company's proprietary protocols are advanced, and use specific processes to obtain desired results. The FDA classifies the Company's process as a unique blood product; therefore, it will be specific and unique to Trinity BioGenics Corp. Additionally, the Company's unique combination of Immune Therapy and Adult Stem Cell treatments are like no other treatment experienced. The Company's Adult Stem Cell protocol is under preparation for Human Clinical Studies.
The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.
The Maui General Store logo is available at http://www.primezone.com/newsroom/prs/?pkgid=1128